{"entity":{"id":"nct00493181","kind":"trial","name":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","aka":[],"tldr":"A phase 2 trial of Oprelvekin in Leukaemia and Chronic myeloid leukaemia, run by M.D. Anderson Cancer Center, completed.","summary":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT00493181 by M.D. Anderson Cancer Center, with 8 participants recorded, started 2005-10 and reaching its primary completion in 2011-01. Interventions recorded: Interleukin-11 (IL-11 or Neumega). Conditions recorded: Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia.\n\nLinked to the drug Oprelvekin because the registry names it among its interventions and Leukaemia and Chronic myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00493181","url":"https://clinicaltrials.gov/study/NCT00493181"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia","cml"],"sections":[],"technologies":[],"targets":[],"drugs":["oprelvekin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00493181","phase":"2","setting":"The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia","sponsor":"M.D. Anderson Cancer Center","enrolled":8,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00493181/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"oprelvekin","kind":"drug","name":"Oprelvekin","route":"/drugs/oprelvekin/"}]}}